obinutuzumab

Ligand id: 6941

Name: obinutuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: obinutuzumab

References
1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al.. (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Blood117 (17): 4519-29. [PMID:21378274]
2. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013)
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Mol. Cancer Ther.12 (10): 2031-42. [PMID:23873847]
3. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. (2013)
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab.
Leuk. Lymphoma,  [Epub ahead of print]. [PMID:23537278]